Imugene (ASX:IMU) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

IMU 주식 개요

임상 단계의 면역 종양학 회사인 Imugene Limited는 호주에서 종양을 치료하고 근절하기 위해 암 환자의 면역 체계를 활성화하는 다양한 면역 치료법을 개발합니다.

IMU 기본 분석
눈송이 점수
가치 평가	1/6
미래 성장	3/6
과거 실적	0/6
재무 상태	6/6
배당금	0/6

보상

수익은 매년 51.93% 증가할 것으로 예상됩니다.

위험 분석

지난 1년 동안 주주가 희석되었습니다.

지난 3개월간 상당한 내부자 매도

Imugene Limited 경쟁사

Dimerix

ASX:DXB

AU$302.4m

Clinuvel Pharmaceuticals

ASX:CUV

AU$770.8m

PYC Therapeutics

ASX:PYC

AU$629.9m

Aroa Biosurgery

ASX:ARX

AU$211.7m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Imugene
과거 주가
현재 주가	AU$0.059
52주 최고치	AU$0.15
52주 최저치	AU$0.039
베타	3.19
11개월 변경	-11.94%
3개월 변경 사항	-43.81%
1년 변경 사항	-33.71%
33년 변화	-84.05%
5년 변화	268.75%
IPO 이후 변화	-39.49%

최근 뉴스 및 업데이트

We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate

Apr 12

Recent updates

Here's Why Shareholders May Consider Paying Imugene Limited's (ASX:IMU) CEO A Little More

Nov 11

Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Aug 22

Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

Feb 28

A Look At Imugene's (ASX:IMU) CEO Remuneration

Feb 17

Announcing: Imugene (ASX:IMU) Stock Soared An Exciting 733% In The Last Five Years

Dec 24

주주 수익률

	IMU	AU Biotechs	AU 마켓
7D	1.7%	1.7%	0.8%
1Y	-33.7%	5.3%	10.3%

수익률 대 산업: IMU 지난 1년 동안 4.2 %를 반환한 Australian Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: IMU 지난 1년 동안 6.7 %를 반환한 Australian 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is IMU's price volatile compared to industry and market?
IMU volatility
IMU Average Weekly Movement	9.7%
Biotechs Industry Average Movement	10.7%
Market Average Movement	8.4%
10% most volatile stocks in AU Market	16.2%
10% least volatile stocks in AU Market	3.2%

안정적인 주가: IMU 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: IMU 의 주간 변동성( 10% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
n/a	n/a	Leslie Chong	www.imugene.com

임상 단계의 면역 종양학 회사인 Imugene Limited는 호주에서 암 환자의 면역 체계를 활성화하여 종양을 치료하고 근절하기 위한 다양한 면역 요법을 개발합니다. 이 회사의 주요 제품은 위암과 유방암의 HER2/neu 수용체에 대한 다클론 항체 반응을 자극하는 HER2 양성 암 백신인 HER-Vaxx입니다. 이 회사의 HER-Vaxx는 위암 2상, 박시니아는 전이성 또는 진행성 고형 종양 환자를 대상으로 한 MAST 임상 1상, 체크백 종양 용해성 바이러스 치료는 전이성 삼중 음성 유방암에 대한 임상 1상 시험을 진행 중입니다.

Imugene Limited 기본 사항 요약

Imugene 의 수익과 매출은 시가총액과 어떻게 비교하나요?
IMU 기본 통계
시가총액	AU$431.87m
수익(TTM)	-AU$89.24m
수익(TTM)	AU$15.03m

28.7x

P/S 비율

-4.8x

P/E 비율

IMU 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
IMU 손익 계산서(TTM)
수익	AU$15.03m
수익 비용	AU$0
총 이익	AU$15.03m
기타 비용	AU$104.27m
수익	-AU$89.24m

최근 보고된 수익

Dec 31, 2023

다음 수익 날짜

n/a

주당 순이익(EPS)	-0.012
총 마진	100.00%
순이익 마진	-593.63%
부채/자본 비율	0%

IMU 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

IMU 주식 개요

보상

위험 분석

Imugene Limited 경쟁사

ASX:DXB

AU$302.4m

ASX:CUV

AU$770.8m

ASX:PYC

AU$629.9m

ASX:ARX

AU$211.7m

가격 내역 및 성능

최근 뉴스 및 업데이트

Executive Chairman recently sold AU$1.1m worth of stock

Imugene Limited Announce Enrolment Opened for Its Expansion Study in Bile Tract Cancer (Cholangiocarcinoma) Patients

We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate

Imugene Limited Announces Phase 1 onCARlytics Solid Tumour Trial Advances to Combination Arm Treatment

Price target decreased by 8.2% to AU$0.34

New minor risk - Share price stability

Recent updates

Executive Chairman recently sold AU$1.1m worth of stock

Imugene Limited Announce Enrolment Opened for Its Expansion Study in Bile Tract Cancer (Cholangiocarcinoma) Patients

We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate

Imugene Limited Announces Phase 1 onCARlytics Solid Tumour Trial Advances to Combination Arm Treatment

Price target decreased by 8.2% to AU$0.34

New minor risk - Share price stability

Imugene Limited, Annual General Meeting, Nov 30, 2023

New minor risk - Profitability

No longer forecast to breakeven

Price target decreased by 14% to AU$0.42

Less than half of directors are independent

Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

Price target decreased by 14% to AU$0.42

Imugene Limited Appoints Paul Woodard as Chief Medical Officer

Imugene Limited Appoints John Byon as Senior Vice President of Clinical Development

Imugene Limited Appoints Dr Bradley Glover as Chief Operating Officer

Imugene Appoints Dr Weitzman Interim Chief Medical Officer

Forecast to breakeven in 2026

Imugene Limited Announces Board Changes

We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate

Price target decreased by 9.8% to AU$0.46

Imugene Limited Announces VAXINIA Trial Advances to Combination Cohort 1 & Monotherapy Cohort 3

Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Imugene Limited Receives Vaxinia Ethics Approval in Australia

Imugene Limited Presents New and First CHECKvacc Data At the 2022 San Antonio Breast Cancer Symposium

Imugene Limited Announces First Patient Dosed in VAXINIA Intravenous Cohort 2

Insufficient new directors

Price target decreased to AU$0.52

Here's Why Shareholders May Consider Paying Imugene Limited's (ASX:IMU) CEO A Little More

Imugene Dose Escalates in Phase I Clinical Trial of New Oncolytic Virus VAXINIA

Independent Non-Executive Director exercised options to buy AU$3.2m worth of stock.

Imugene Limited Announces That First Patient Dosed in VAXINIA Intratumoral Cohort 2

Imugene Limited, Annual General Meeting, Nov 17, 2022

Price target decreased to AU$0.51

Imugene Limited Announces First patient IV dosed in VAXINIA Phase 1 clinical trial

Imugene Limited Announces That Australian Government's Office of the Gene Technology Regulator (Ogtr) Has Granted Imugene the Dir Licence Required to Expand Its Vaxinia Phase 1 Clinical Trial Within Australia

Consensus forecasts updated

Price target decreased to AU$0.52

Imugene Limited Doses First Patient in nextHERIZON Phase 2 Trial

Imugene Appoints Jakob Dupont as Non- Executive Director

Imugene Dose Escalates in Phase I Clinical Trial of New Oncolytic Virus VAXINIA

Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Imugene Limited Announces First Cohort 3 Patient Dosed in Clinical Trial of CHECKvacc

Imugene Limited Appoints Mike Tonroe as Chief Financial Officer, Effective from September 2022

Imugene Limited Announces Appointment of Dr. Sharon Yavrom as Executive Director, Clinical Scientist

Imugene Limited Announces Final HER-Vaxx Phase 2 Trial Overall Survival Results

Consensus forecasts updated

Independent Non-Executive Director exercised options to buy AU$1.5m worth of stock.

Imugene Limited Announces Board Changes

City of Hope and Imugene Announce First Patient Dosed in Phase 1 Trial to Test Cancer-Killing Oncolytic Virus Against Solid Tumors

Imugene Limited Receives Ethics Approval to Start Phase 2 nextHERIZON Clinical Trial of Cancer Immunotherapy HER-VAXX

Imugene Limited Announces First Cohort 2 Patient Dosed in Clinical Trial of CHECKvacc

Consensus forecasts updated

Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

Imugene Limited Announces Appointment of Steven Cha as Chief Medical Officer and Member of the Executive Management Team

Imugene Limited Receives Notice of Grant from the European Patent Office for Patent Application Number

Imugene Completes Phase 1a Monotherapy Dose Escalation of Immunotherapy PD1-Vaxx

Executive Chairman recently sold AU$37m worth of stock

Imugene Limited Receives US Food and Drug Administration (FDA) Investigational New Drug (IND) Approval to Initiate A Phase I Clinical Trial of its Oncolytic Virotherapy Candidate, Vaxinia (CF33-hNIS, HOV2)